1. Home
  2. STC vs IBRX Comparison

STC vs IBRX Comparison

Compare STC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STC
  • IBRX
  • Stock Information
  • Founded
  • STC 1893
  • IBRX 2014
  • Country
  • STC United States
  • IBRX United States
  • Employees
  • STC N/A
  • IBRX N/A
  • Industry
  • STC Specialty Insurers
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STC Finance
  • IBRX Health Care
  • Exchange
  • STC Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • STC 2.0B
  • IBRX 2.3B
  • IPO Year
  • STC N/A
  • IBRX N/A
  • Fundamental
  • Price
  • STC $74.46
  • IBRX $2.60
  • Analyst Decision
  • STC Buy
  • IBRX Strong Buy
  • Analyst Count
  • STC 2
  • IBRX 6
  • Target Price
  • STC $77.50
  • IBRX $9.83
  • AVG Volume (30 Days)
  • STC 147.6K
  • IBRX 9.0M
  • Earning Date
  • STC 10-22-2025
  • IBRX 11-11-2025
  • Dividend Yield
  • STC 2.68%
  • IBRX N/A
  • EPS Growth
  • STC 99.80
  • IBRX N/A
  • EPS
  • STC 3.11
  • IBRX N/A
  • Revenue
  • STC $2,668,739,000.00
  • IBRX $56,600,000.00
  • Revenue This Year
  • STC $13.62
  • IBRX $629.94
  • Revenue Next Year
  • STC $12.41
  • IBRX $109.91
  • P/E Ratio
  • STC $23.99
  • IBRX N/A
  • Revenue Growth
  • STC 13.92
  • IBRX 4227.22
  • 52 Week Low
  • STC $56.39
  • IBRX $1.83
  • 52 Week High
  • STC $78.44
  • IBRX $7.48
  • Technical
  • Relative Strength Index (RSI)
  • STC 60.94
  • IBRX 59.00
  • Support Level
  • STC $71.44
  • IBRX $2.32
  • Resistance Level
  • STC $75.19
  • IBRX $2.67
  • Average True Range (ATR)
  • STC 1.77
  • IBRX 0.12
  • MACD
  • STC -0.11
  • IBRX 0.04
  • Stochastic Oscillator
  • STC 80.44
  • IBRX 84.09

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: